PMID

Data

Article Title

Organization

Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors.

Sichuan University

Discovery of a Dual PRMT5-PRMT7 Inhibitor.

University of Toronto

Exploration of cyanine compounds as selective inhibitors of protein arginine methyltransferases: synthesis and biological evaluation.

The University of Georgia

Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.

University of North Carolina At Chapel Hill

Diamidine compounds for selective inhibition of protein arginine methyltransferase 1.

The University of Georgia

Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.

Entremed

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.

TBA

Synthesis and evaluation of carbocyanine dyes as PRMT inhibitors and imaging agents.

Georgia State University

Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.

Sun Yat-Sen University

Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.

Institut De G£N£Tique Et De Biologie Mol£Culaire Et Cellulaire

Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.

Csir-Indian Institute of Chemical Biology

Paradoxical Increase of Permeability and Lipophilicity with the Increasing Topological Polar Surface Area within a Series of PRMT5 Inhibitors.

Novartis Institutes For Biomedical Research

Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.

Mirati Therapeutics

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5?MTA Complex for the Treatment of

Mirati Therapeutics

Fragment-Based Design of a Potent MAT2a Inhibitor and

Astrazeneca

Discovery of

China Pharmaceutical University

Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.

China Pharmaceutical University

Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.

The Broad Institute of Mit and Harvard

5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.

Chinese Academy of Sciences

The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.

Merck

A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode.

Janssen Pharmaceutica

Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.

University of Michigan Medical School

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.

Epizyme

Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5).

Merck

New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.

University College London

Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening.

University of Toronto

Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation.

Punjabi University

Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia.

Chinese Academy of Sciences

Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.

Prelude Therapeutics

The development and characterization of a chemical probe targeting PRMT1 over PRMT5.

University of North Florida

Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.

University of Jinan

Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.

Prelude Therapeutics

Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.

Sun Yat-Sen University

LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.

Lilly Research Laboratories

Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell Proliferation.

Zhejiang Sci-Tech University

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Eli Lilly

Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma.

Ligand Pharmaceuticals